Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Nov 22, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer

Nov 10, 2022

Marker Therapeutics Reports Q3 2022 Operating and Financial Results

Sep 13, 2022

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 08, 2022

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Aug 11, 2022

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 04, 2022

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

May 13, 2022

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 04, 2022

Marker Therapeutics to Present Four Posters on its T Cell-Based Immunotherapies at the 2022 International Society for Cell & Gene Therapy Annual Meeting

Apr 26, 2022

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

Mar 17, 2022

Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 31 - 40 of 109

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2024 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy